Skip to content

    Cancer Health Center

    Font Size
    A
    A
    A

    Hypopharyngeal Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage IV Hypopharyngeal Cancer

    Resectable Hypopharyngeal Cancer

    The management of patients with resectable hypopharyngeal cancer is complex and requires multidisciplinary input to establish the optimal treatment regimen. New surgical techniques and reconstructions using the gastric pull-up operation or free jejunal transfers have greatly reduced the morbidity associated with resection of these tumors and have almost eliminated the need for multistage reconstructions. This has greatly aided the combined treatment regimens because these patients have a high likelihood of beginning postoperative radiation therapy within 3 to 4 weeks following resection.

    Recommended Related to Cancer

    General Information About Adult Primary Liver Cancer

    Incidence and Mortality Estimated new cases and deaths from liver and intrahepatic bile duct cancer in the United States in 2014:[1] New cases: 33,190. Deaths: 23,000. Hepatocellular carcinoma (HCC) is relatively uncommon in the United States, although its incidence is rising, principally in relation to the spread of hepatitis C virus (HCV) infection.[2] HCC is the most common solid tumor worldwide and the third leading cause of cancer-related deaths.[3,4] Both local extension...

    Read the General Information About Adult Primary Liver Cancer article > >

    Details of surgical procedures and their modifications of radiation fields or dosage schedules are not specifically designated here because of legitimate variations in techniques that, according to various retrospective data, give similar survival results in different treatment centers. This group of patients should be managed by surgeons and radiation oncologists who are skilled in the multiple procedures and techniques available, and who are actively and frequently involved in the care of these patients.

    Standard treatment options:

    1. The combination of surgery and radiation, most often postoperative as seen in a follow-up study of preoperative versus postoperative radiation therapy (PORT) (RTOG-7303), has become the usual form of therapy for this group of patients in the United States.[1,2]
    2. Neoadjuvant chemotherapy as given in clinical trials has been used to shrink tumors and render them more definitively treatable with either surgery or radiation. Chemotherapy is given prior to the other modalities, hence the designation, neoadjuvant, to distinguish it from standard adjuvant therapy, which is given after or during definitive therapy with radiation or after surgery. Many drug combinations have been used in neoadjuvant chemotherapy. Neoadjuvant chemotherapy is commonly used to treat patients presenting with advanced disease to improve locoregional control or survival, despite the lack of data from randomized, prospective trials.[3] The use of neoadjuvant chemotherapy to increase organ preservation has also been advocated. In a prospective randomized trial, referred to as the GORTEC-TREMPLIN trial (NCT00169247), the European Organization for the Research and Treatment of Cancer compared surgery plus PORT to induction chemotherapy (i.e., cisplatin plus 5-fluorouracil [5-FU]) followed by radiation in responding patients.[4] Local and regional failures were similar in both groups. Although median survival was 25 months in the immediate surgery arm of the study and 44 months in the induction chemotherapy arm (P = .006), 5-year disease-free and overall survival (OS) were the same. A functional larynx was preserved in 42% of patients at 3 years and 35% at 5 years in patients who were receiving induction chemotherapy.[4][Level of evidence: 1iiA, 1iiC] In contrast to this, another randomized, prospective trial has demonstrated a statistically significant survival advantage for patients undergoing chemotherapy (i.e., cisplatin plus 5-FU) followed by laryngopharyngectomy and PORT when compared with chemotherapy and radiation therapy.[5][Level of evidence: 1iiA,1iiC] Although organ preservation was not discussed, chemotherapy in combination with radiation therapy without surgery should not be considered standard.
    3. Patients with stage IV hypopharyngeal cancer should be considered for treatment with combined postoperative, adjuvant radiation therapy and chemotherapy. In a prospective, randomized trial, postoperative, adjuvant radiation therapy alone was compared to postoperative, adjuvant radiation therapy plus concurrent chemotherapy. Both the OS (P <.01) and the disease-free survival (P <.02) were better in the group of patients receiving radiation therapy plus concurrent chemotherapy.[6][Level of evidence: 1iiA] In another study, primary site preservation was improved, though OS was not improved when chemotherapy was administered concomitantly with radiation therapy.[7,8]
    1 | 2
    Next Article:

    Today on WebMD

    man holding lung xray
    What you need to know.
    stem cells
    How they work for blood cancers.
     
    woman wearing pink ribbon
    Separate fact from fiction.
    Colorectal cancer cells
    Symptoms, screening tests, and more.
     
    Jennifer Goodman Linn self-portrait
    Blog
    what is your cancer risk
    HEALTH CHECK
     
    colorectal cancer treatment advances
    Video
    breast cancer overview slideshow
    SLIDESHOW
     
    prostate cancer overview
    SLIDESHOW
    lung cancer overview slideshow
    SLIDESHOW
     
    ovarian cancer overview slideshow
    SLIDESHOW
    Actor Michael Douglas
    Article